Medical Care
Global Next Generation Cancer Diagnostics Market Research Report 2024
- Mar 12, 24
- ID: 114332
- Pages: 98
- Figures: 193
- Views: 24
The global Next Generation Cancer Diagnostics market was valued at US$ 6198.2 million in 2023 and is anticipated to reach US$ 20950 million by 2030, witnessing a CAGR of 18.5% during the forecast period 2024-2030.
North American market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Next Generation Cancer Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Next Generation Cancer Diagnostics include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health and Myriad Genetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Next Generation Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Cancer Diagnostics.
Report Scope
The Next Generation Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next Generation Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next Generation Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cepheid
Koninklijke Philips N.V
F. Hoffmann-La Roche Ltd
Qiagen
Novartis AG
Abbott
Thermo Fisher Scientific
Opko Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer
Genomic Health
Illumina
Hologic
Almac Group
Janssen Global Services
Sysmex Corporation
Segment by Type
Next Generation Sequencing
qPCR & Multiplexing
DNA Microarrays
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Next Generation Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Next Generation Cancer Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Next Generation Cancer Diagnostics include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health and Myriad Genetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Next Generation Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Cancer Diagnostics.
Report Scope
The Next Generation Cancer Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Next Generation Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Next Generation Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cepheid
Koninklijke Philips N.V
F. Hoffmann-La Roche Ltd
Qiagen
Novartis AG
Abbott
Thermo Fisher Scientific
Opko Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer
Genomic Health
Illumina
Hologic
Almac Group
Janssen Global Services
Sysmex Corporation
Segment by Type
Next Generation Sequencing
qPCR & Multiplexing
DNA Microarrays
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Cancer Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Next Generation Sequencing
1.2.3 qPCR & Multiplexing
1.2.4 DNA Microarrays
1.2.5 Others
1.3 Market by Application
1.3.1 Global Next Generation Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Cancer Diagnostics Market Perspective (2019-2030)
2.2 Next Generation Cancer Diagnostics Growth Trends by Region
2.2.1 Global Next Generation Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next Generation Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Next Generation Cancer Diagnostics Market Dynamics
2.3.1 Next Generation Cancer Diagnostics Industry Trends
2.3.2 Next Generation Cancer Diagnostics Market Drivers
2.3.3 Next Generation Cancer Diagnostics Market Challenges
2.3.4 Next Generation Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
3.4 Global Next Generation Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2023
3.5 Next Generation Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Next Generation Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Next Generation Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Cancer Diagnostics Breakdown Data by Type
4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Next Generation Cancer Diagnostics Breakdown Data by Application
5.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Next Generation Cancer Diagnostics Market Size (2019-2030)
6.2 North America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next Generation Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Next Generation Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next Generation Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cepheid
11.1.1 Cepheid Company Detail
11.1.2 Cepheid Business Overview
11.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
11.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.1.5 Cepheid Recent Development
11.2 Koninklijke Philips N.V
11.2.1 Koninklijke Philips N.V Company Detail
11.2.2 Koninklijke Philips N.V Business Overview
11.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
11.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.2.5 Koninklijke Philips N.V Recent Development
11.3 F. Hoffmann-La Roche Ltd
11.3.1 F. Hoffmann-La Roche Ltd Company Detail
11.3.2 F. Hoffmann-La Roche Ltd Business Overview
11.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
11.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.3.5 F. Hoffmann-La Roche Ltd Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Detail
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
11.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.4.5 Qiagen Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
11.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.5.5 Novartis AG Recent Development
11.6 Abbott
11.6.1 Abbott Company Detail
11.6.2 Abbott Business Overview
11.6.3 Abbott Next Generation Cancer Diagnostics Introduction
11.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
11.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Opko Health
11.8.1 Opko Health Company Detail
11.8.2 Opko Health Business Overview
11.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
11.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.8.5 Opko Health Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Detail
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
11.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.9.5 Myriad Genetics Recent Development
11.10 Agilent Technologies
11.10.1 Agilent Technologies Company Detail
11.10.2 Agilent Technologies Business Overview
11.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
11.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.10.5 Agilent Technologies Recent Development
11.11 GE Healthcare
11.11.1 GE Healthcare Company Detail
11.11.2 GE Healthcare Business Overview
11.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
11.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.11.5 GE Healthcare Recent Development
11.12 PerkinElmer
11.12.1 PerkinElmer Company Detail
11.12.2 PerkinElmer Business Overview
11.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
11.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.12.5 PerkinElmer Recent Development
11.13 Genomic Health
11.13.1 Genomic Health Company Detail
11.13.2 Genomic Health Business Overview
11.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
11.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.13.5 Genomic Health Recent Development
11.14 Illumina
11.14.1 Illumina Company Detail
11.14.2 Illumina Business Overview
11.14.3 Illumina Next Generation Cancer Diagnostics Introduction
11.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.14.5 Illumina Recent Development
11.15 Hologic
11.15.1 Hologic Company Detail
11.15.2 Hologic Business Overview
11.15.3 Hologic Next Generation Cancer Diagnostics Introduction
11.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.15.5 Hologic Recent Development
11.16 Almac Group
11.16.1 Almac Group Company Detail
11.16.2 Almac Group Business Overview
11.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
11.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.16.5 Almac Group Recent Development
11.17 Janssen Global Services
11.17.1 Janssen Global Services Company Detail
11.17.2 Janssen Global Services Business Overview
11.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
11.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.17.5 Janssen Global Services Recent Development
11.18 Sysmex Corporation
11.18.1 Sysmex Corporation Company Detail
11.18.2 Sysmex Corporation Business Overview
11.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
11.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.18.5 Sysmex Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Next Generation Sequencing
1.2.3 qPCR & Multiplexing
1.2.4 DNA Microarrays
1.2.5 Others
1.3 Market by Application
1.3.1 Global Next Generation Cancer Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Cancer Diagnostics Market Perspective (2019-2030)
2.2 Next Generation Cancer Diagnostics Growth Trends by Region
2.2.1 Global Next Generation Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Next Generation Cancer Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Next Generation Cancer Diagnostics Market Dynamics
2.3.1 Next Generation Cancer Diagnostics Industry Trends
2.3.2 Next Generation Cancer Diagnostics Market Drivers
2.3.3 Next Generation Cancer Diagnostics Market Challenges
2.3.4 Next Generation Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
3.4 Global Next Generation Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2023
3.5 Next Generation Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Next Generation Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Next Generation Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Cancer Diagnostics Breakdown Data by Type
4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2025-2030)
5 Next Generation Cancer Diagnostics Breakdown Data by Application
5.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Next Generation Cancer Diagnostics Market Size (2019-2030)
6.2 North America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
6.4 North America Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Next Generation Cancer Diagnostics Market Size (2019-2030)
7.2 Europe Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
7.4 Europe Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Next Generation Cancer Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Next Generation Cancer Diagnostics Market Size (2019-2030)
9.2 Latin America Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Next Generation Cancer Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cepheid
11.1.1 Cepheid Company Detail
11.1.2 Cepheid Business Overview
11.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
11.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.1.5 Cepheid Recent Development
11.2 Koninklijke Philips N.V
11.2.1 Koninklijke Philips N.V Company Detail
11.2.2 Koninklijke Philips N.V Business Overview
11.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
11.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.2.5 Koninklijke Philips N.V Recent Development
11.3 F. Hoffmann-La Roche Ltd
11.3.1 F. Hoffmann-La Roche Ltd Company Detail
11.3.2 F. Hoffmann-La Roche Ltd Business Overview
11.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
11.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.3.5 F. Hoffmann-La Roche Ltd Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Detail
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
11.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.4.5 Qiagen Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
11.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.5.5 Novartis AG Recent Development
11.6 Abbott
11.6.1 Abbott Company Detail
11.6.2 Abbott Business Overview
11.6.3 Abbott Next Generation Cancer Diagnostics Introduction
11.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
11.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Opko Health
11.8.1 Opko Health Company Detail
11.8.2 Opko Health Business Overview
11.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
11.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.8.5 Opko Health Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Detail
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
11.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.9.5 Myriad Genetics Recent Development
11.10 Agilent Technologies
11.10.1 Agilent Technologies Company Detail
11.10.2 Agilent Technologies Business Overview
11.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
11.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.10.5 Agilent Technologies Recent Development
11.11 GE Healthcare
11.11.1 GE Healthcare Company Detail
11.11.2 GE Healthcare Business Overview
11.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
11.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.11.5 GE Healthcare Recent Development
11.12 PerkinElmer
11.12.1 PerkinElmer Company Detail
11.12.2 PerkinElmer Business Overview
11.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
11.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.12.5 PerkinElmer Recent Development
11.13 Genomic Health
11.13.1 Genomic Health Company Detail
11.13.2 Genomic Health Business Overview
11.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
11.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.13.5 Genomic Health Recent Development
11.14 Illumina
11.14.1 Illumina Company Detail
11.14.2 Illumina Business Overview
11.14.3 Illumina Next Generation Cancer Diagnostics Introduction
11.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.14.5 Illumina Recent Development
11.15 Hologic
11.15.1 Hologic Company Detail
11.15.2 Hologic Business Overview
11.15.3 Hologic Next Generation Cancer Diagnostics Introduction
11.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.15.5 Hologic Recent Development
11.16 Almac Group
11.16.1 Almac Group Company Detail
11.16.2 Almac Group Business Overview
11.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
11.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.16.5 Almac Group Recent Development
11.17 Janssen Global Services
11.17.1 Janssen Global Services Company Detail
11.17.2 Janssen Global Services Business Overview
11.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
11.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.17.5 Janssen Global Services Recent Development
11.18 Sysmex Corporation
11.18.1 Sysmex Corporation Company Detail
11.18.2 Sysmex Corporation Business Overview
11.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
11.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2019-2024)
11.18.5 Sysmex Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Next Generation Sequencing
Table 3. Key Players of qPCR & Multiplexing
Table 4. Key Players of DNA Microarrays
Table 5. Key Players of Others
Table 6. Global Next Generation Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Next Generation Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Next Generation Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Next Generation Cancer Diagnostics Market Share by Region (2019-2024)
Table 10. Global Next Generation Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Next Generation Cancer Diagnostics Market Share by Region (2025-2030)
Table 12. Next Generation Cancer Diagnostics Market Trends
Table 13. Next Generation Cancer Diagnostics Market Drivers
Table 14. Next Generation Cancer Diagnostics Market Challenges
Table 15. Next Generation Cancer Diagnostics Market Restraints
Table 16. Global Next Generation Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Next Generation Cancer Diagnostics Market Share by Players (2019-2024)
Table 18. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2023)
Table 19. Ranking of Global Top Next Generation Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Next Generation Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Next Generation Cancer Diagnostics Product Solution and Service
Table 23. Date of Enter into Next Generation Cancer Diagnostics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next Generation Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 27. Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 29. Global Next Generation Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 31. Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 33. North America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Next Generation Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Cepheid Company Detail
Table 49. Cepheid Business Overview
Table 50. Cepheid Next Generation Cancer Diagnostics Product
Table 51. Cepheid Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 52. Cepheid Recent Development
Table 53. Koninklijke Philips N.V Company Detail
Table 54. Koninklijke Philips N.V Business Overview
Table 55. Koninklijke Philips N.V Next Generation Cancer Diagnostics Product
Table 56. Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 57. Koninklijke Philips N.V Recent Development
Table 58. F. Hoffmann-La Roche Ltd Company Detail
Table 59. F. Hoffmann-La Roche Ltd Business Overview
Table 60. F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Product
Table 61. F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 62. F. Hoffmann-La Roche Ltd Recent Development
Table 63. Qiagen Company Detail
Table 64. Qiagen Business Overview
Table 65. Qiagen Next Generation Cancer Diagnostics Product
Table 66. Qiagen Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 67. Qiagen Recent Development
Table 68. Novartis AG Company Detail
Table 69. Novartis AG Business Overview
Table 70. Novartis AG Next Generation Cancer Diagnostics Product
Table 71. Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 72. Novartis AG Recent Development
Table 73. Abbott Company Detail
Table 74. Abbott Business Overview
Table 75. Abbott Next Generation Cancer Diagnostics Product
Table 76. Abbott Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 77. Abbott Recent Development
Table 78. Thermo Fisher Scientific Company Detail
Table 79. Thermo Fisher Scientific Business Overview
Table 80. Thermo Fisher Scientific Next Generation Cancer Diagnostics Product
Table 81. Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 82. Thermo Fisher Scientific Recent Development
Table 83. Opko Health Company Detail
Table 84. Opko Health Business Overview
Table 85. Opko Health Next Generation Cancer Diagnostics Product
Table 86. Opko Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 87. Opko Health Recent Development
Table 88. Myriad Genetics Company Detail
Table 89. Myriad Genetics Business Overview
Table 90. Myriad Genetics Next Generation Cancer Diagnostics Product
Table 91. Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 92. Myriad Genetics Recent Development
Table 93. Agilent Technologies Company Detail
Table 94. Agilent Technologies Business Overview
Table 95. Agilent Technologies Next Generation Cancer Diagnostics Product
Table 96. Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 97. Agilent Technologies Recent Development
Table 98. GE Healthcare Company Detail
Table 99. GE Healthcare Business Overview
Table 100. GE Healthcare Next Generation Cancer Diagnostics Product
Table 101. GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 102. GE Healthcare Recent Development
Table 103. PerkinElmer Company Detail
Table 104. PerkinElmer Business Overview
Table 105. PerkinElmer Next Generation Cancer Diagnostics Product
Table 106. PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 107. PerkinElmer Recent Development
Table 108. Genomic Health Company Detail
Table 109. Genomic Health Business Overview
Table 110. Genomic Health Next Generation Cancer Diagnostics Product
Table 111. Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 112. Genomic Health Recent Development
Table 113. Illumina Company Detail
Table 114. Illumina Business Overview
Table 115. Illumina Next Generation Cancer Diagnostics Product
Table 116. Illumina Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 117. Illumina Recent Development
Table 118. Hologic Company Detail
Table 119. Hologic Business Overview
Table 120. Hologic Next Generation Cancer Diagnostics Product
Table 121. Hologic Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 122. Hologic Recent Development
Table 123. Almac Group Company Detail
Table 124. Almac Group Business Overview
Table 125. Almac Group Next Generation Cancer Diagnostics Product
Table 126. Almac Group Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 127. Almac Group Recent Development
Table 128. Janssen Global Services Company Detail
Table 129. Janssen Global Services Business Overview
Table 130. Janssen Global Services Next Generation Cancer Diagnostics Product
Table 131. Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 132. Janssen Global Services Recent Development
Table 133. Sysmex Corporation Company Detail
Table 134. Sysmex Corporation Business Overview
Table 135. Sysmex Corporation Next Generation Cancer Diagnostics Product
Table 136. Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 137. Sysmex Corporation Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next Generation Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Next Generation Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Next Generation Sequencing Features
Figure 4. qPCR & Multiplexing Features
Figure 5. DNA Microarrays Features
Figure 6. Others Features
Figure 7. Global Next Generation Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Next Generation Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Next Generation Cancer Diagnostics Report Years Considered
Figure 13. Global Next Generation Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Next Generation Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Next Generation Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 16. Global Next Generation Cancer Diagnostics Market Share by Players in 2023
Figure 17. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Next Generation Cancer Diagnostics Revenue in 2023
Figure 19. North America Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 21. United States Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 25. Germany Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Next Generation Cancer Diagnostics Market Share by Region (2019-2030)
Figure 33. China Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 41. Mexico Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 45. Turkey Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Cepheid Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 48. Koninklijke Philips N.V Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 49. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 50. Qiagen Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 51. Novartis AG Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 52. Abbott Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 54. Opko Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 55. Myriad Genetics Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 56. Agilent Technologies Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 57. GE Healthcare Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 58. PerkinElmer Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 59. Genomic Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 60. Illumina Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 61. Hologic Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 62. Almac Group Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 63. Janssen Global Services Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 64. Sysmex Corporation Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Next Generation Sequencing
Table 3. Key Players of qPCR & Multiplexing
Table 4. Key Players of DNA Microarrays
Table 5. Key Players of Others
Table 6. Global Next Generation Cancer Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Next Generation Cancer Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Next Generation Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Next Generation Cancer Diagnostics Market Share by Region (2019-2024)
Table 10. Global Next Generation Cancer Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Next Generation Cancer Diagnostics Market Share by Region (2025-2030)
Table 12. Next Generation Cancer Diagnostics Market Trends
Table 13. Next Generation Cancer Diagnostics Market Drivers
Table 14. Next Generation Cancer Diagnostics Market Challenges
Table 15. Next Generation Cancer Diagnostics Market Restraints
Table 16. Global Next Generation Cancer Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Next Generation Cancer Diagnostics Market Share by Players (2019-2024)
Table 18. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2023)
Table 19. Ranking of Global Top Next Generation Cancer Diagnostics Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Next Generation Cancer Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Next Generation Cancer Diagnostics Product Solution and Service
Table 23. Date of Enter into Next Generation Cancer Diagnostics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Next Generation Cancer Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2019-2024)
Table 27. Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Next Generation Cancer Diagnostics Revenue Market Share by Type (2025-2030)
Table 29. Global Next Generation Cancer Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2019-2024)
Table 31. Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Next Generation Cancer Diagnostics Revenue Market Share by Application (2025-2030)
Table 33. North America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Next Generation Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Next Generation Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Cepheid Company Detail
Table 49. Cepheid Business Overview
Table 50. Cepheid Next Generation Cancer Diagnostics Product
Table 51. Cepheid Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 52. Cepheid Recent Development
Table 53. Koninklijke Philips N.V Company Detail
Table 54. Koninklijke Philips N.V Business Overview
Table 55. Koninklijke Philips N.V Next Generation Cancer Diagnostics Product
Table 56. Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 57. Koninklijke Philips N.V Recent Development
Table 58. F. Hoffmann-La Roche Ltd Company Detail
Table 59. F. Hoffmann-La Roche Ltd Business Overview
Table 60. F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Product
Table 61. F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 62. F. Hoffmann-La Roche Ltd Recent Development
Table 63. Qiagen Company Detail
Table 64. Qiagen Business Overview
Table 65. Qiagen Next Generation Cancer Diagnostics Product
Table 66. Qiagen Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 67. Qiagen Recent Development
Table 68. Novartis AG Company Detail
Table 69. Novartis AG Business Overview
Table 70. Novartis AG Next Generation Cancer Diagnostics Product
Table 71. Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 72. Novartis AG Recent Development
Table 73. Abbott Company Detail
Table 74. Abbott Business Overview
Table 75. Abbott Next Generation Cancer Diagnostics Product
Table 76. Abbott Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 77. Abbott Recent Development
Table 78. Thermo Fisher Scientific Company Detail
Table 79. Thermo Fisher Scientific Business Overview
Table 80. Thermo Fisher Scientific Next Generation Cancer Diagnostics Product
Table 81. Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 82. Thermo Fisher Scientific Recent Development
Table 83. Opko Health Company Detail
Table 84. Opko Health Business Overview
Table 85. Opko Health Next Generation Cancer Diagnostics Product
Table 86. Opko Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 87. Opko Health Recent Development
Table 88. Myriad Genetics Company Detail
Table 89. Myriad Genetics Business Overview
Table 90. Myriad Genetics Next Generation Cancer Diagnostics Product
Table 91. Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 92. Myriad Genetics Recent Development
Table 93. Agilent Technologies Company Detail
Table 94. Agilent Technologies Business Overview
Table 95. Agilent Technologies Next Generation Cancer Diagnostics Product
Table 96. Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 97. Agilent Technologies Recent Development
Table 98. GE Healthcare Company Detail
Table 99. GE Healthcare Business Overview
Table 100. GE Healthcare Next Generation Cancer Diagnostics Product
Table 101. GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 102. GE Healthcare Recent Development
Table 103. PerkinElmer Company Detail
Table 104. PerkinElmer Business Overview
Table 105. PerkinElmer Next Generation Cancer Diagnostics Product
Table 106. PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 107. PerkinElmer Recent Development
Table 108. Genomic Health Company Detail
Table 109. Genomic Health Business Overview
Table 110. Genomic Health Next Generation Cancer Diagnostics Product
Table 111. Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 112. Genomic Health Recent Development
Table 113. Illumina Company Detail
Table 114. Illumina Business Overview
Table 115. Illumina Next Generation Cancer Diagnostics Product
Table 116. Illumina Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 117. Illumina Recent Development
Table 118. Hologic Company Detail
Table 119. Hologic Business Overview
Table 120. Hologic Next Generation Cancer Diagnostics Product
Table 121. Hologic Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 122. Hologic Recent Development
Table 123. Almac Group Company Detail
Table 124. Almac Group Business Overview
Table 125. Almac Group Next Generation Cancer Diagnostics Product
Table 126. Almac Group Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 127. Almac Group Recent Development
Table 128. Janssen Global Services Company Detail
Table 129. Janssen Global Services Business Overview
Table 130. Janssen Global Services Next Generation Cancer Diagnostics Product
Table 131. Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 132. Janssen Global Services Recent Development
Table 133. Sysmex Corporation Company Detail
Table 134. Sysmex Corporation Business Overview
Table 135. Sysmex Corporation Next Generation Cancer Diagnostics Product
Table 136. Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2019-2024) & (US$ Million)
Table 137. Sysmex Corporation Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Next Generation Cancer Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Next Generation Cancer Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Next Generation Sequencing Features
Figure 4. qPCR & Multiplexing Features
Figure 5. DNA Microarrays Features
Figure 6. Others Features
Figure 7. Global Next Generation Cancer Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Next Generation Cancer Diagnostics Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Next Generation Cancer Diagnostics Report Years Considered
Figure 13. Global Next Generation Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Next Generation Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Next Generation Cancer Diagnostics Market Share by Region: 2023 VS 2030
Figure 16. Global Next Generation Cancer Diagnostics Market Share by Players in 2023
Figure 17. Global Top Next Generation Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Next Generation Cancer Diagnostics Revenue in 2023
Figure 19. North America Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 21. United States Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 25. Germany Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Next Generation Cancer Diagnostics Market Share by Region (2019-2030)
Figure 33. China Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 41. Mexico Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Next Generation Cancer Diagnostics Market Share by Country (2019-2030)
Figure 45. Turkey Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Next Generation Cancer Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Cepheid Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 48. Koninklijke Philips N.V Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 49. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 50. Qiagen Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 51. Novartis AG Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 52. Abbott Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 54. Opko Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 55. Myriad Genetics Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 56. Agilent Technologies Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 57. GE Healthcare Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 58. PerkinElmer Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 59. Genomic Health Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 60. Illumina Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 61. Hologic Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 62. Almac Group Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 63. Janssen Global Services Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 64. Sysmex Corporation Revenue Growth Rate in Next Generation Cancer Diagnostics Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Paint Leveling Agent Market Insights, Forecast to 2030
Dec 22, 24
Global Paint Adhesion Promoters Market Insights, Forecast to 2030
Dec 22, 24
Global Paint Rheological Additives Market Insights, Forecast to 2030
Dec 22, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232